Powder: -20°C for 3 years | In solvent: -80°C for 1 year
RTI-13951-33 is an effective and brain-penetrant GPR88 agonist (EC50: 25 nM, in GPR88 cAMP functional assay).
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 12,800 | 8-10周 | ||
50 mg | ¥ 16,800 | 8-10周 | ||
100 mg | ¥ 21,500 | 8-10周 |
产品描述 | RTI-13951-33 is an effective and brain-penetrant GPR88 agonist (EC50: 25 nM, in GPR88 cAMP functional assay). |
靶点活性 | GPR88:(EC50)25 nM |
体外活性 | RTI-13951-33 poorly inhibits SERT (IC50: 25.1 ± 2.7 μM). RTI-13951-33 elevates [35S]-GTPγS binding (EC50: 535 nM) in mouse striatal membranes but not in membranes from GPR88 KO mice. RTI-13951-33 has weak affinities at kappa opioid receptor (KOR; Ki, 2.29 μM), vesicular monoamine transporter (VMAT; Ki, 4.23 μM), and moderate affinity at serotonin transporter (SERT; Ki, 0.75 μM) [1]. |
体内活性 | RTI-13951-33 (10 and 20 mg/kg, i.p.) dose-dependently reduces alcohol lever responses in a rat model of alcohol self-administration. RTI-13951-33 (10 mg/kg, i.p.) has sufficient brain penetration, with t1/2 of 48 min and 87 min in rat plasma and brain [1]. |
分子量 | 459.58 |
分子式 | C28H33N3O3 |
CAS No. | 2244884-08-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
RTI-13951-33 2244884-08-8 Endocrinology/Hormones GPCR/G Protein GPR RTI1395133 RTI 13951 33 Inhibitor inhibitor inhibit